187 related articles for article (PubMed ID: 33461589)
1. Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer.
El Khoury LY; Fu S; Hlady RA; Wagner RT; Wang L; Eckel-Passow JE; Castle EP; Stanton ML; Thompson RH; Parker AS; Ho TH; Robertson KD
Clin Epigenetics; 2021 Jan; 13(1):12. PubMed ID: 33461589
[TBL] [Abstract][Full Text] [Related]
2. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
3. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
[TBL] [Abstract][Full Text] [Related]
4. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
6. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.
Patel N; Hakansson A; Ohtake S; Muraki P; Proudfout JA; Liu Y; Webber L; Ibarra A; Liu VYT; Davicioni E; Chamie K; Pantuck A; Shuch B
Cancer Med; 2023 Mar; 12(5):6437-6444. PubMed ID: 36397716
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
[TBL] [Abstract][Full Text] [Related]
11. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
[TBL] [Abstract][Full Text] [Related]
12. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
[TBL] [Abstract][Full Text] [Related]
13. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA; Brannon AR; Parker JS; Fisher JC; Sen O; Kattan MW; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Miller CR; Nielsen ME; Rathmell WK
Eur Urol; 2014 Jul; 66(1):77-84. PubMed ID: 24613583
[TBL] [Abstract][Full Text] [Related]
14. A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma.
Shi S; Ye S; Wu X; Xu M; Zhuo R; Liao Q; Xi Y
Yonsei Med J; 2019 Nov; 60(11):1013-1020. PubMed ID: 31637882
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
Li P; Liu J; Li J; Liu P
Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma.
Kubiliūtė R; Žukauskaitė K; Žalimas A; Ulys A; Sabaliauskaitė R; Bakavičius A; Želvys A; Jankevičius F; Jarmalaitė S
J Cancer Res Clin Oncol; 2022 Feb; 148(2):361-375. PubMed ID: 34689221
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma.
Mehra R; Nallandhighal S; Cotta B; Knuth Z; Su F; Kasputis A; Zhang Y; Wang R; Cao X; Udager AM; Dhanasekaran SM; Cieslik MP; Morgan TM; Salami SS
JCO Precis Oncol; 2024 May; 8():e2300565. PubMed ID: 38810179
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.
Lebdai S; Verhoest G; Parikh H; Jacquet SF; Bensalah K; Chautard D; Rioux Leclercq N; Azzouzi AR; Bigot P
Urol Oncol; 2015 Feb; 33(2):69.e11-8. PubMed ID: 25035170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
